Rep. Julie Johnson Sells Off Shares of Abbott Laboratories (NYSE:ABT)

Key Points

• Representative Julie Johnson sold shares of Abbott Laboratories (NYSE:ABT) valued between $1,001 and $15,000 on August 14th, 2025, as disclosed in a filing on September 11th.
• Abbott Laboratories recently traded at $133.92, representing a 1.0% increase, with a market capitalization of approximately $233.08 billion.
• Abbott Laboratories is experiencing positive analyst sentiments, with a consensus rating of "Moderate Buy" and a target price of $144.47.

Representative Julie Johnson (D-Texas) recently sold shares of Abbott Laboratories NYSE: ABT. In a filing disclosed on September 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on August 14th. The trade occurred in the Representative's "CHASE BROKERAGE ACCOUNT (3935)" account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Parker-Hannifin NYSE: PH on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Fidelity National Information Services NYSE: FIS on 8/14/2025.
• Sold $1,001 - $15,000 in shares of ConocoPhillips NYSE: COP on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Dover NYSE: DOV on 8/14/2025.
• Sold $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 8/14/2025.

Abbott Laboratories Stock Up 1.0%

ABT traded up $1.27 on Friday, reaching $133.92. The company's stock had a trading volume of 5,700,290 shares, compared to its average volume of 4,674,658. The stock has a 50 day moving average of $130.41 and a two-hundred day moving average of $131.29. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $233.08 billion, a price-to-earnings ratio of 16.78, a P/E/G ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm's quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. BTIG Research lowered their price target on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a report on Friday, July 18th. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Jefferies Financial Group raised Abbott Laboratories from a "hold" rating to a "buy" rating and increased their price objective for the company from $143.00 to $145.00 in a report on Friday, July 18th. William Blair raised Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Finally, Mizuho increased their price objective on Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, July 16th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $144.47.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.46% of the company's stock.

Institutional Investors Weigh In On Abbott Laboratories

Several large investors have recently modified their holdings of ABT. IMG Wealth Management Inc. raised its stake in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after purchasing an additional 167 shares during the last quarter. Hughes Financial Services LLC purchased a new stake in shares of Abbott Laboratories during the first quarter worth approximately $27,000. Abound Financial LLC purchased a new position in Abbott Laboratories in the first quarter worth $28,000. Elequin Capital LP purchased a new position in Abbott Laboratories in the first quarter worth $30,000. Finally, Wormser Freres Gestion purchased a new position in Abbott Laboratories in the fourth quarter worth $32,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas' 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Johnson (Democratic Party) ran for election to the U.S. House to represent Texas' 32nd Congressional District. She won in the general election on November 5, 2024. Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson's career experience includes working as an attorney.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.